Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2023-03-15 Proxy Solicitation & In…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a definitive proxy statement filed under Schedule 14A with the SEC, related to the company's 2023 Annual Meeting of Stockholders. It discusses solicitation of proxies, director nominations, and voting instructions. The document is not the proxy statement itself but a solicitation material under Rule 14a-12, which is a type of proxy solicitation material. The content focuses on urging shareholders to vote for board nominees and provides information about the meeting and voting process. This fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (11,879 characters), indicating it is not a brief announcement but a detailed solicitation material. Therefore, the correct classification is PSI with high confidence.
2023-03-15 English
FORM DEFC14A
Proxy Solicitation & Information Statement
2023-03-15 English
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and references to Rule 14a-101 and Section 14(a) of the Securities Exchange Act of 1934. It is a preliminary proxy statement for the 2023 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. The content includes detailed information about the matters to be voted on at the Annual Meeting, including election of directors, ratification of the independent auditor, and a shareholder proposal. It also contains voting instructions and background on the solicitation. The document is not an annual report, earnings release, or any other financial report but is specifically a proxy solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the proxy statement itself, not just an announcement or notice.
2023-03-13 English
FORM 4
Director's Dealing
2023-03-13 English
FORM 4
Director's Dealing
2023-03-13 English
FORM 4
Director's Dealing
2023-03-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.